Onderzoeker
Jan De Bleecker
- Disciplines:Neurologische en neuromusculaire ziekten, Histologie, Neuroanatomie, Musculo-skeletale systemen, Neurofysiologie, Inflammatie, Neurowetenschappen niet elders geclassificeerd
Affiliaties
- Vakgroep Hoofd en Huid (Departement)
Lid
Vanaf1 okt 2018 → Heden - Vakgroep Inwendige ziekten (Departement)
Lid
Vanaf1 feb 1999 → 30 sep 2018
Publicaties
11 - 20 van 86
- Risk of malignant hyperthermia in patients carrying a variant in the ryanodine receptor 1 gene(2022)Volume: 9
Auteurs: L Janssens, J De Puydt, Sofie Symoens, Jan De Bleecker
Pagina's: S296 - S296 - Het ‘three territory sign’ als een merker van occulte maligniteit bij een beroerte(2022)
Auteurs: Marc Lemmerling, Jan De Bleecker
Pagina's: 221 - 227 - Post-intervention status in patients with refractory myasthenia gravis treated with eculizumab during REGAIN and its open-label extension(2021)
Auteurs: R Mantegazza, GI Wolfe, S Muppidi, H Wiendl, KP Fujita, FL O'Brien, Booth HDE, JF Howard, REGAIN Study Group, Jan De Bleecker
Pagina's: E610 - E618 - High-throughput imaging of ATG9A distribution as a diagnostic functional assay for adaptor protein complex 4-associated hereditary spastic paraplegia(2021)
Auteurs: Darius Ebrahimi-Fakhari, Julian E. Alecu, Barbara Brechmann, Marvin Ziegler, Kathrin Eberhardt, Hellen Jumo, Angelica D'Amore, Parham Habibzadeh, Mohammad Ali Faghihi, Jan De Bleecker, et al.
- Efficacy and safety of rozanolixizumab in moderate to severe generalized myasthenia gravis : a phase 2 randomized control trial(2021)
Auteurs: V Bril, M Benatar, H Andersen, J Vissing, M Brock, B Greve, P Kiessling, F Woltering, L Griffin, P Van den Bergh, et al.
Pagina's: E853 - E865 - Efficacy and safety of Bimagrumab in sporadic inclusion body myositis : long-term extension of RESILIENT(2021)
Auteurs: AA Amato, MG Hanna, PM Machado, UA Badrising, H Chinoy, O Benveniste, AK Karanam, M Wu, LB Tankó, AA Schubert-Tennigkeit, et al.
Pagina's: e1595 - e1607 - Myositis-specific and myositis-associated autoantibodies predict trajectories of damage over time in idiopathic inflammatory myopathies(2021)Volume: 50
Auteurs: F Espinosa-Ortega, M Holmqvist, K Lodin, M Dastmalchi, MG Danieli, J Venkovsky, J Knitza, S Oliveira, LP Diederichsen, L Wedderburn, et al.
Pagina's: 49 - 50 - Safety and efficacy of oral levosimendan in people with amyotrophic lateral sclerosis (the REFALS study) : a randomised, double-blind, placebo-controlled phase 3 trial(2021)
Auteurs: Merit Cudkowicz, Angela Genge, Nicholas Maragakis, Susanne Petri, Leonard van den Berg, Valtteri V Aho, Toni Sarapohja, Mikko Kuoppamäki, Chris Garratt, Ammar Al-Chalabi, et al.
Pagina's: 821 - 831 - In-depth phenotypic description of TBK1 mutations ; a frequent cause of FTD and ALS in the Flanders-Belgian population(2021)Volume: 28
Auteurs: H Gossye, S Van Mossevelde, J Van der Zee, Y Vermeiren, N De Roeck, Jan De Bleecker, P Cras, P De Deyn, S Engelborghs, C Van Broeckhoven
Pagina's: 93 - 94 - Case report : olanzapine post-injection delirium/sedation syndrome mimicking brainstem-thrombosis(2021)
Auteurs: Arthur Pollentier, Marijke Vergaelen, Jan De Bleecker
Pagina's: 1383 - 1384